Viewing Study NCT05816694



Ignite Creation Date: 2024-05-06 @ 6:51 PM
Last Modification Date: 2024-10-26 @ 2:56 PM
Study NCT ID: NCT05816694
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-04-18
First Post: 2023-03-27

Brief Title: The Efficacy and Safety of Nanoparticle Albumin-bound NAB-Paclitaxel Plus Cisolation Versus CEP Cisplatin EpirubicinCyclophosphamide in Induction Therapy for Thymoma a Study for a Single-center Prospective Phase II Randomized Controlled Train
Sponsor: Peng Liu
Organization: Shanghai Zhongshan Hospital

Study Overview

Official Title: The Efficacy and Safety of Nanoparticle Albumin-bound NAB-Paclitaxel Plus Cisolation Versus CEP Cisplatin EpirubicinCyclophosphamide in Induction Therapy for Thymoma a Study for a Single-center Prospective Phase II Randomized Controlled Train
Status: NOT_YET_RECRUITING
Status Verified Date: 2023-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study for a single-center prospective phase II randomized controlled train to assess the efficacy and safety of Induction therapy on thymoma Methods patients with thymoma stage Ⅲ and stage Ⅳa were treated with 2 cycles of NAB-paclitaxel plus Cisolation Paclitaxel For InjectionAalbumin Bound125 mgm2 Day 1 Day8 Cisplatin 75 mgm2 Day 1of each 3-week cycleor CEPcisplatin 50 mgm2 Day 1 epirubicin 75 mgm2 Day 1cyclophosphamide 500 mgm2 Day 1 of each 3-week cycle Following chemotherapy to evaluate the patient for operation Patients without undergo surgery will be continued to receive 2 cycles of Primary chemotherap
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None